Nexus Surgical and Medicare Ltd

Nexus Surgical and Medicare Ltd., a micro-cap medical essentials trading company, reported its Q4 FY26 results with net profit surging to ₹0.24 crores, marking a 41.18% quarter-on-quarter increase and an impressive 166.67% year-on-year growth. However, the company's revenue trajectory remained erratic, with net sales declining 30.03% sequentially to ₹2.05 crores, despite posting a 38.51% year-on-year gain. Trading at ₹19.90 with an ₹11.00 crore market capitalisation, the stock has delivered a 5.63% return over the past year, marginally underperforming its NBFC sector peers.

Nexus Surgical and Medicare Ltd, a micro-cap player in the Non Banking Financial Company (NBFC) sector, has demonstrated a notable turnaround in its recent quarterly performance. The company’s financial trend has shifted from flat to positive, driven by improved revenue growth and margin expansion in the quarter ended March 2026. This development comes amid a challenging market environment and a mixed performance relative to broader indices such as the Sensex.

Surging to a fresh 52-week high of Rs 25 on 12 May 2026, Nexus Surgical and Medicare Ltd has demonstrated remarkable price momentum, outperforming its sector and the broader market despite a bearish backdrop for the Sensex.

With a 62.97% gain over the past year, Nexus Surgical and Medicare Ltd surged to a fresh 52-week high of Rs 24.51 on 11 May 2026, outpacing the Sensex which declined 3.74% over the same period. This milestone caps a five-day winning streak that has propelled the stock 35.04% higher, underscoring a powerful momentum shift despite a broadly weaker market backdrop.

Nexus Surgical and Medicare Ltd has seen its investment rating upgraded from Strong Sell to Sell as of 1 April 2026, driven primarily by changes in its technical outlook despite persistent fundamental challenges. The micro-cap NBFC’s technical indicators have shifted from mildly bullish to sideways, prompting a reassessment of its near-term prospects amid flat financial performance and valuation concerns.

Nexus Surgical and Medicare Ltd, a micro-cap player in the Non-Banking Financial Company (NBFC) sector, has been downgraded from a Sell to a Strong Sell rating as of 25 March 2026. The revision reflects a deterioration in technical indicators, valuation concerns, and a flat financial trend, despite the company’s historically strong returns over the long term. This comprehensive analysis explores the four key parameters that triggered the rating change: Quality, Valuation, Financial Trend, and Technicals.

Nexus Surgical and Medicare Ltd has seen its investment rating upgraded from Strong Sell to Sell as of 6 March 2026, driven primarily by improvements in technical indicators despite persistent valuation and financial trend challenges. The company’s technical outlook has shifted to mildly bullish, prompting a reassessment of its near-term prospects, although fundamental concerns remain.

Nexus Surgical and Medicare Ltd, a micro-cap player in the Non Banking Financial Company (NBFC) sector, has recently formed a Golden Cross—a significant technical indicator where the 50-day moving average crosses above the 200-day moving average. This development often heralds a bullish breakout, signalling a potential long-term momentum shift and trend reversal for the stock.

Nexus Surgical and Medicare Ltd, a player in the Non Banking Financial Company (NBFC) sector, has seen its investment rating downgraded from Sell to Strong Sell as of 25 February 2026. This shift reflects a combination of deteriorating technical indicators, expensive valuation metrics, flat financial trends, and weakening overall quality scores, signalling caution for investors amid a challenging market environment.

Nexus Surgical and Medicare Ltd has seen its investment rating upgraded from Strong Sell to Sell as of 20 Feb 2026, driven primarily by a shift in technical indicators signalling a mild bullish trend. Despite this upgrade, the company continues to face valuation and fundamental challenges, with flat recent financial performance and a high price-to-book ratio. This article analyses the four key parameters—Quality, Valuation, Financial Trend, and Technicals—that influenced the rating change and what it means for investors.

Nexus Surgical and Medicare Ltd, a player in the Non Banking Financial Company (NBFC) sector, has seen its investment rating downgraded from Sell to Strong Sell as of 16 February 2026. This shift reflects a combination of deteriorating technical indicators, expensive valuation metrics, flat financial trends, and weakening overall quality assessments, signalling caution for investors amid a challenging market backdrop.

Nexus Surgical and Medicare Ltd has seen its investment rating upgraded from Strong Sell to Sell, driven primarily by a shift in technical indicators signalling a mild bullish trend. Despite this positive technical momentum, the company continues to face challenges in valuation and financial performance, which temper the overall outlook for investors.

Nexus Surgical and Medicare Ltd is rated Strong Sell by MarketsMOJO. This rating was last updated on 11 Nov 2025, reflecting a shift from the previous 'Sell' grade. However, the analysis and financial metrics discussed here represent the stock's current position as of 26 December 2025, providing investors with an up-to-date view of its performance and outlook.

Nexus Surgical and Medicare has reached a new 52-week low of Rs.13.26, marking a significant decline in its share price amid a volatile trading session. The stock's performance contrasts sharply with broader market trends, reflecting ongoing pressures within the Non Banking Financial Company (NBFC) sector.

Nexus Surgical, a microcap player in the Non Banking Financial Company (NBFC) sector, has experienced a revision in its market evaluation reflecting recent shifts in its financial and technical outlook. This adjustment comes amid a backdrop of subdued profit growth and valuation concerns, impacting investor sentiment and stock performance.